Patient Information Leaflet
Paliperidone Teva 50 mg prolonged-release injectable suspension EFG
Paliperidone Teva 75 mg prolonged-release injectable suspension EFG
Paliperidone Teva 100 mg prolonged-release injectable suspension EFG
Paliperidone Teva 150 mg prolonged-release injectable suspension EFG
Initial treatment pack:
Paliperidone Teva 150 mg and Paliperidone Teva 100 mg prolonged-release injectable suspension EFG
Read this leaflet carefully before you start using this medicine because
it contains important information for you.
1. What is Paliperidone Teva and what is it used for
2. What you need to know before you start using Paliperidone Teva
3. How to use Paliperidone Teva
4. Possible side effects
5. Storage of Paliperidone Teva
6. Contents of the pack and additional information
Paliperidona Teva contains the active ingredient paliperidone, which belongs to the class of antipsychotic medications and is used as maintenance treatment for symptoms of schizophrenia in adult patients who are stabilized with paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may start treatment with Paliperidona Teva without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are normally not present. For example, a person with schizophrenia may hear voices or see things that do not exist (known as hallucinations), have false beliefs (known as delusions) or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimuli or may have difficulty speaking in a clear and logical manner. People who suffer from this disorder may also feel depressed, anxious, guilty, or tense.
Paliperidona Teva may help alleviate the symptoms of your illness and prevent them from recurring.
No use paliperidonapaliperidona
Advertencias y precauciones
Consult your doctor, pharmacist, or nurse before starting to use Paliperidona Teva.
This medication has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with similar medications may have an increased risk of stroke or death (see section 4, possible side effects).
All medications have side effects, and some of the side effects of this medication may worsen symptoms of other conditions. For this reason, it is essential to discuss with your doctor any of the following diseases, which may worsen during treatment with this medication:
If you have any of these diseases, please consult your doctor as it may be necessary to adjust your dose or keep you under observation for a while.
Because in very rare cases, a dangerously low number of a type of white blood cell necessary to fight infections in the blood has been observed in patients treated with this medication, your doctor may check your white blood cell count.
Even if you have previously tolerated paliperidona oral or risperidona, rare allergic reactions may occur after receiving Paliperidona Teva injections. Seek immediate medical help if you experience a skin rash, swelling of the throat, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medication may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medication, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medication may mask the normal response of the body to the ingestion of toxic substances or other conditions, there is a possibility that it may mask the symptoms of other conditions.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which may cause eye damage. If you are planning to have eye surgery, be sure to inform your ophthalmologist that you are using this medication.
Niños y adolescentes
Do not use this medication in children under 18 years old.
Otros medicamentos y Paliperidona Teva
Inform your doctor if you are using, have used recently, or may need to use any other medication.
The use of this medication with carbamazepine (an antiepileptic and mood stabilizer) may require a change in your dose of this medication.
Since this medication primarily acts on the brain, interaction with other medications that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medications, opioids, antihistamines, and sleep medications.
Since this medication may lower blood pressure, you should be careful if you use it with other medications that also lower blood pressure.
This medication may reduce the effect of medications for Parkinson's disease and restless leg syndrome (e.g., levodopa).
This medication may cause an anomaly in the electrocardiogram (ECG) that shows a prolonged period for an electrical impulse to travel through a certain part of the heart (known as "prolongation of the QT interval"). Other medications that have this effect include some medications used to treat heart rhythm or to treat infections, as well as other antipsychotics.
If you are prone to seizures, this medication may increase your chances of experiencing them. Other medications that have this effect include some medications used to treat depression or to treat infections, as well as other antipsychotics.
Paliperidona Teva should be used with caution with medications that increase the activity of the central nervous system (psycho-stimulants such as methylphenidate).
Uso de Paliperidona Teva con alcohol
Alcohol should be avoided.
Embarazo,lactancia
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication. Do not use this medication during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidona in the last trimester of pregnancy (last three months of pregnancy): tremors, rigidity, and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, contact your doctor.
This medication may pass from mother to baby through breast milk and may harm the baby. Therefore, do not breastfeed while using this medication.
Conducción y uso de máquinas
During treatment with this medication, dizziness, extreme fatigue, and vision problems (see section 4) may occur. This should be taken into account when requiring maximum attention, such as when driving or operating machines.
Paliperidona Teva contiene sodio
This medication contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Your doctor or another healthcare professional will administer this medication. Your doctor will tell you when to receive the next injection. It is essential that you do not miss any scheduled doses. If you cannot attend your appointment with your doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medication in the upper arm approximately one week apart. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from long-acting risperidone injectable to this medication, you will receive the first injection of this medication (between 25 mg and 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
Your doctor may increase or decrease the amount of medication you receive at the time of the scheduled monthly injection based on your symptoms.
Patients with kidney problems
Your doctor may adjust the dose of this medication based on your renal function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medication if you have moderate or severe kidney problems.
Patients with advanced age
Your doctor may reduce the dose of this medication if your kidney function is decreased.
If you take more Paliperidone Teva than you should
You will receive this medication under medical supervision, so it is unlikely that you will receive an excessive dose.
Patients who have received an excessive amount of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, electrocardiogram abnormalities (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you stop using Paliperidone Teva
If you stop receiving your injections, you will lose the effects of the medication. Do not stop using this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
The following side effects may occur:
Very common side effects: can affect more than 1 in 10 patients
Common side effects: can affect up to 1 in 10 patients
Uncommon side effects: can affect up to 1 in 100 patients
Rare side effects: can affect up to 1 in 10,000 patients
Unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your doctor or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the pre-filled syringe and on the box after “CAD or EXP”. The expiration date is the last day of the month indicated.
This medication does not require any special storage conditions.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Paliperidone Teva
The active ingredient is paliperidone
Each Paliperidone Teva 50 mg pre-filled syringe contains 78 mg of palmitate of paliperidone in 0.5 ml
Each Paliperidone Teva 75 mg pre-filled syringe contains 117 mg of palmitate of paliperidone in 0.75 ml
Each Paliperidone Teva 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml
Each Paliperidone Teva 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
Starting treatment pack:
Each Paliperidone Teva 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml
Each Paliperidone Teva 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
The other components are:
Polysorbate 20
Macrogol 4000
Citric acid monohydrate
Dipotassium phosphate
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injection
Appearance of the product and contents of the pack
Paliperidone Teva is a white to off-white prolonged-release injectable suspension, which comes in a pre-filled syringe (prolonged-release injection)
Each pack contains 1 pre-filled syringe and 2 needles
Starting treatment pack:
Each pack contains 1 pack of Paliperidone Teva 150 mg and 1 pack of Paliperidone Teva 100 mg
Only some pack sizes may be marketed
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Responsible manufacturer:
Actavis Group PTC ehf.
Dalshraun 1,
Hafnarfjörður 220.
Iceland
Further information about this medicinal product can be obtained by contacting the local representative of the marketing authorization holder:
Teva Pharma, S.L.U
C/ Anabel Segura, 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108, Madrid (Spain)
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Germany: | Paliperidon-ratiopharm 25 mg Depot-Injektionssuspension Paliperidon-ratiopharm 50 mg Depot-Injektionssuspension Paliperidon-ratiopharm 75 mg Depot-Injektionssuspension Paliperidon-ratiopharm 100 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg und 100 mg Depot-Injektionssuspension |
Austria: | Paliperidon ratiopharm 25 mg Depot-Injektionssuspension Paliperidon ratiopharm 50 mg Depot-Injektionssuspension Paliperidon ratiopharm 75 mg Depot-Injektionssuspension Paliperidon ratiopharm 100 mg Depot-Injektionssuspension Paliperidon ratiopharm 150 mg Depot-Injektionssuspension Paliperidon ratiopharm Starterpackung 100 mg und Paliperidon ratiopharm 150 mg Depot-Injektionssuspension |
Belgium | Paliperidone Teva 25 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 50 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 75 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 100 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 150 mg suspensie voor injectie met verlengde afgifte/ suspension injectable à libération prolongée/ Depot-Injektionssuspension Paliperidone Teva 150 mg & 100 mg suspensie voor injectie met verlengde afgifte/suspension injectable à libération prolongée/Depot-Injektionssuspension |
Bulgaria: | ??????????? ???? 75 mg ??????????? ????????? ? ???????? ????????????? ??????????? ???? 100 mg ??????????? ????????? ? ???????? ????????????? ??????????? ???? 150 mg ??????????? ????????? ? ???????? ????????????? |
Croatia: | Paliperidon Teva 50 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 75 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 100 mg suspenzija za injekciju s produljenim oslobadanjem Paliperidon Teva 150 mg suspenzija za injekciju s produljenim oslobadanjem |
Cyprus: | Paliperidone/Teva Pharma 75 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma100 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 150 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης |
Denmark: | Paliperidon Teva |
Estonia: | Paliperidone Teva |
Finland: | Paliperidone ratiopharm 25 mg injektioneste, depotsuspensio Paliperidone ratiopharm 50 mg injektioneste, depotsuspensio Paliperidone ratiopharm 75 mg injektioneste, depotsuspensio Paliperidone ratiopharm 100 mg injektioneste, depotsuspensio Paliperidone ratiopharm 150 mg injektioneste, depotsuspensio Paliperidone ratiopharm 100 mg + 150 mg injektioneste, depotsuspensio |
France: | PALIPERIDONE TEVA 25mg suspension injectable à libération prolongée PALIPERIDONE TEVA 50mg suspension injectable à libération prolongée PALIPERIDONE TEVA 75mg suspension injectable à libération prolongée PALIPERIDONE TEVA 100mg suspension injectable à libération prolongée PALIPERIDONE TEVA 150mg suspension injectable à libération prolongée |
Greece: | Paliperidone/Teva Pharma 75 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 100 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης Paliperidone/Teva Pharma 150 mg εν?σιμο εναι?ρημα παρατεταμ?νης αποδ?σμευσης |
Hungary: | Paliperidon Teva 25 mg retard szuszpenziósinjekció Paliperidon Teva 50 mg retard szuszpenziós injekció Paliperidon Teva 75 mg retard szuszpenziós injekció Paliperidon Teva 100 mg retard szuszpenziós injekció Paliperidon Teva 150 mg retard szuszpenziós Injekció Paliperidon Teva 150 mg és 100 mg retard szuszpenziós injekció |
Iceland: | Paliperidon Teva |
Ireland: | Paliperidone Teva 25mg Prolonged-release Suspension for Injection Paliperidone Teva 50mg Prolonged-release Suspension for Injection Paliperidone Teva 75mg Prolonged-release Suspension for Injection Paliperidone Teva 100mg Prolonged-release Suspension for Injection Paliperidone Teva 150mg Prolonged-release Suspension for Injection Paliperidone Teva 150mg and 100mg Prolonged-release Suspension for Injection |
Italy: | Paliperidone Teva Italia |
Lithuania: | Paliperidone Teva 50 mg pailginto atpalaidavimo injekcine suspensija Paliperidone Teva 75 mg pailginto atpalaidavimo injekcine suspensija Paliperidone Teva 100 mg pailginto atpalaidavimo injekcine suspensija Palieridone Teva 150 mg pailginto atpalaidavimo injekcine suspensija |
Luxembourg: | Paliperidon-ratiopharm 25 mg Depot-Injektionssuspension Paliperidon-ratiopharm 50 mg Depot-Injektionssuspension Paliperidon-ratiopharm 75 mg Depot-Injektionssuspension Paliperidon-ratiopharm 100 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg Depot-Injektionssuspension Paliperidon-ratiopharm 150 mg und 100 mg Depot-Injektionssuspension |
Netherlands: | Paliperidon Teva 25 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 50 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 75 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 100 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 150 mg, suspensie voor injectie met verlengde afgifte Paliperidon Teva 150 mg, en 100 mg, suspensie voor injectie met verlengde afgifte |
Norway: | Paliperidon Teva |
Poland: | Paliperidone Teva |
Portugal: | Paliperidona Teva |
Romania: | Paliperidona Teva 50 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 75 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 100 mg suspensie injectabila cu eliberare prelungita Paliperidona Teva 150 mg suspensie injectabila cu eliberare prelungita |
Slovakia: | Paliperidón Teva 25 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 50 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 75 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva100 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 150 mg injekcná suspenzia s predlženým uvolnovaním Paliperidón Teva 150 mg injekcná suspenzia s predlženým uvolnovaním a Paliperidón Teva 100 mg injekcná suspenzia s predlženým uvolnovaním |
Slovenia: | Paliperidon Teva 50 mg suspenzija s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 75 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 100 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 150 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje Paliperidon Teva 150 mg in 100 mg suspenzija za injiciranje s podaljšanim sprošcanjem za injiciranje |
Spain: | Paliperidona Teva 50 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 75 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 100 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 150 mg suspension inyectable de liberación prolongada EFG Paliperidona Teva 150 mg y Paliperidona Teva 100 mg suspensión inyectable de liberación prolongada EFG |
Sweden: | Paliperidon Teva |
United Kingdom (Northern Ireland): | Paliperidone Teva 25 mg Prolonged-release Suspension for Injection Paliperidone Teva 50 mg Prolonged-release Suspension for Injection Paliperidone Teva 75 mg Prolonged-release Suspension for Injection Paliperidone Teva 100 mg Prolonged-release Suspension for Injection Paliperidone Teva 150 mg Prolonged-release Suspension for Injection Paliperidone Teva 150 mg and 100 mg Prolonged-release Suspension for Injection Treatment Initiation Pack |
Last review date of this leaflet:February 2024
Other sources of information
The detailed information on this medicinal product is available on the website of theSpanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
This information is intended solely for healthcare professionals and should be read in conjunction with the full prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use only. It should be visually inspected to detect any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The pack contains a pre-filled syringe and two safety needles (one 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle and one 23 gauge 1 inch [25.4 mm x 0.64 mm] needle) for intramuscular injection. Paliperidone Teva is also available in a treatment initiation pack containing two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first dose of Paliperidone Teva (150 mg) is administered on Day 1 in the DELTOIDES muscle using the needle for DELTOIDES injection. The second dose of Paliperidone Teva (100 mg) is administered also in the DELTOIDES muscle one week later (Day 8) using the needle for DELTOIDES injection.
If the patient is switched from risperidone long-acting injectable to Paliperidone Teva, the first injection of Paliperidone Teva (dose range 25 mg to 150 mg) can be administered in the DELTOIDES muscle or in the GLUTEAL muscle, using the appropriate needle for the injection site, at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in both the DELTOIDES and GLUTEAL muscles using the appropriate needle for the injection site.
In the case of DELTOIDES injection, if the patient weighs <90>23kg, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with blue shaft); if the patient weighs?90 kg, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with grey shaft).
In the case of GLUTEAL injection, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with grey shaft).
8a
8b
8c
The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.